CanBas Co (TSE:4575) Asset Impairment Charge : 円0.00 Mil (TTM As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is CanBas Co Asset Impairment Charge?

CanBas Co's Asset Impairment Charge for the three months ended in Dec. 2023 was 円0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 was 円0.00 Mil.

CanBas Co Asset Impairment Charge Historical Data

The historical data trend for CanBas Co's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanBas Co Asset Impairment Charge Chart

CanBas Co Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Asset Impairment Charge

Get a 7-Day Free Trial

CanBas Co Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

CanBas Co Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

CanBas Co Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of CanBas Co's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

CanBas Co (TSE:4575) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CanBas Co Ltd (TSE:4575) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

9 Toriyoko-cho, Shizuoka, JPN, 410-0891

Website

http://www.canbas.co.jp

CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.

CanBas Co (TSE:4575) Headlines

No Headlines